Coyote Pharmaceuticals Targets ALS

Via de website http://www.als.net/
Kwam ik hierop: [color=#FF0000:32nmzi80][link werkt niet meer][/color:32nmzi80]

MENLO PARK, Calif., Oct. 1, 2012 /PRNewswire via COMTEX/ -- Coyote Pharmaceuticals, Inc., an emerging biopharmaceutical company focused on orphan and neurodegenerative diseases, today announced that it is moving forward with a "dual-track" clinical program for its lead compound, CNS-102, for treating Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease (AD). The first phase of the clinical program, targeting ALS, is set to commence in 2013.

Aernout